Literature DB >> 10908571

Evidence that the serum inhibitor of hyaluronidase may be a member of the inter-alpha-inhibitor family.

K Mio1, O Carrette, H I Maibach, R Stern.   

Abstract

A study of the uncharacterized serum inhibitors of hyaluronidase, first described half a century ago, was undertaken. Activity was measured against bovine testicular hyaluronidase using a microtiter-based assay and reverse hyaluronan substrate gel zymography. The predominant inhibitory activity was magnesium-dependent and could be eliminated by protease or chondroitinase digestion and by heat treatment. Kinetics of inhibition were similar against hyaluronidases from testis and snake and bee venoms. The inhibitor had no effect on Streptomyces hyaluronidase, indicating that inhibition was not through protection of the hyaluronan substrate. Inhibition levels in serum were increased in mice following carbon tetrachloride or interleukin-1 injection, inducers of the acute-phase response. Reverse zymography identified a predominant band of 120-kDa relative molecular size, with two bands of greater and one of smaller size. The predominant protein was tentatively identified as a member of the inter-alpha-inhibitor family. Inhibition was also observed using either purified inter-alpha-inhibitor or an inter-alpha-inhibitor-related 120-kDa complex. Inter-alpha-inhibitor, found in the hyaluronan-rich cumulus mass surrounding mammalian ova and the coat of fibroblasts and mesothelial cells, may function to stabilize such matrices by protecting against hyaluronidase degradation. Turnover of circulating hyaluronan is extraordinarily rapid, with a half-life of 2-5 min. Prompt increases in levels of serum hyaluronan occur in patients with shock, septicemia, or massive burns, increases that can be attributed, in part, to suppression of degradation by these acute-phase reactants, the inhibitors of hyaluronidase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908571     DOI: 10.1074/jbc.M005428200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Reverse hyaluronan substrate gel zymography procedure for the detection of hyaluronidase inhibitors.

Authors:  K Mio; R Stern
Journal:  Glycoconj J       Date:  2000-11       Impact factor: 2.916

2.  Hyaluronan is not elevated in urine or serum in Hutchinson-Gilford Progeria Syndrome.

Authors:  Leslie B Gordon; Ingrid A Harten; Anthony Calabro; Geetha Sugumaran; Antonei B Csoka; W Ted Brown; Vincent Hascall; Bryan P Toole
Journal:  Hum Genet       Date:  2003-05-01       Impact factor: 4.132

3.  Low cholesterol triggers membrane microdomain-dependent CD44 shedding and suppresses tumor cell migration.

Authors:  Toshiyuki Murai; Yuusuke Maruyama; Kazuhiro Mio; Hidetoshi Nishiyama; Mitsuo Suga; Chikara Sato
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

Review 4.  The Inter-α-Trypsin Inhibitor Family: Versatile Molecules in Biology and Pathology.

Authors:  Megan S Lord; James Melrose; Anthony J Day; John M Whitelock
Journal:  J Histochem Cytochem       Date:  2020-07-08       Impact factor: 2.479

Review 5.  Defining the versican interactome in lung health and disease.

Authors:  Fengying Tang; Jourdan E Brune; Mary Y Chang; Stephen R Reeves; William A Altemeier; Charles W Frevert
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-01       Impact factor: 5.282

6.  Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines.

Authors:  Carol de la Motte; Julie Nigro; Amit Vasanji; Hyunjin Rho; Sean Kessler; Sudip Bandyopadhyay; Silvio Danese; Claudio Fiocchi; Robert Stern
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

7.  Synthesis and biological evaluations of oleanolic acid indole derivatives as hyaluronidase inhibitors with enhanced skin permeability.

Authors:  Hao He; Huifang Li; Toyosi Akanji; Shengli Niu; Zhujun Luo; Dongli Li; Navindra P Seeram; Panpan Wu; Hang Ma
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

8.  Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Authors:  Sanna Rosengren; Samuel S Dychter; Marie A Printz; Lei Huang; Richard I Schiff; Hans-Peter Schwarz; John K McVey; Fred H Drake; Dan C Maneval; Don A Kennard; Gregory I Frost; Barry J Sugarman; Douglas B Muchmore
Journal:  AAPS J       Date:  2015-05-13       Impact factor: 4.009

9.  Hyaluronidase: An overview of its properties, applications, and side effects.

Authors:  Hyunwook Jung
Journal:  Arch Plast Surg       Date:  2020-07-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.